Thrombotic Thrombocytopenic Purpura (TTP)

2
Pipeline Programs
2
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
2 programs
1
TAK-755Phase 34 trials
Recombinant ADAMTS13N/A1 trial
Active Trials
NCT06441578Recruiting40Est. Sep 2032
NCT05770219Approved For Marketing
NCT05714969Active Not Recruiting33Est. Jun 2026
+2 more trials
Octapharma
OctapharmaAustria - Vienna
1 program
1
UniplasPhase 31 trial
Active Trials
NCT00411801Terminated8Est. Feb 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
TakedaTAK-755
TakedaTAK-755
OctapharmaUniplas
TakedaTAK-755
TakedaRecombinant ADAMTS13

Clinical Trials (6)

Total enrollment: 210 patients across 6 trials

NCT04683003TakedaTAK-755

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Start: Apr 2021Est. completion: Mar 202777 patients
Phase 3Recruiting
NCT03393975TakedaTAK-755

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Start: Oct 2017Est. completion: May 202452 patients
Phase 3Completed
NCT00411801OctapharmaUniplas

Safety and Efficacy Study to Compare Uniplas With Cryosupernatant Plasma in Thrombotic Thrombocytopenic Purpura (TTP)

Start: May 2007Est. completion: Feb 20088 patients
Phase 3Terminated
NCT05714969TakedaTAK-755

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)

Start: Mar 2023Est. completion: Jun 202633 patients
Phase 2Active Not Recruiting
NCT05770219TakedaTAK-755

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

N/AApproved For Marketing
NCT06441578TakedaRecombinant ADAMTS13

A Survey of Recombinant ADAMTS13 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Start: May 2024Est. completion: Sep 203240 patients
N/ARecruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 actively recruiting trials targeting 210 patients
2 companies competing in this space